This year marks a milestone for the Indonesian clinical trial community. On January 18 th , the Indonesian Association for the Study of Medicinals (IASMED) held a clinical trial seminar. They invited Head of BPOM - Prof. dr. Taruna Ikrar, M. Biomed, Ph.D, Head of BB Binomika - Indri Rooslamiati, M.Sc., Apt., as well as several clinical trial sites, sponsors, and CROs.

"We have numerous hospitals and we have mapped clinical site capabilities across Indonesia. With the upcoming progress in site development all over Indonesia, we increase the site capability within the country. Additionally, we are working to enhance the regulatory startup process to make it faster than the current situation. We aim to implement many improvements to build the clinical trial ecosystem, with significant progress expected as soon as 2025," said Mrs. Indri in her keynote speech.
Prof. dr. Taruna also delivered his speech on BPOM’s strategy to boost clinical research in Indonesia. In his presentation, he said, “As a scientist and government official, my strategy focuses on fostering collaboration and integration among academia, business, and governance. Considering the limited number of clinical trial approvals, BPOM also concern to create a more conducive clinical trial ecosystem in Indonesia. Additionally, by 2025, we aim to obtain WHO Listed Authority (WLA), positioning Indonesia on the global stage.”

Equilab also had the opportunity to showcase their capabilities and success stories in vaccine and
infectious disease clinical trials. As the largest CRO in Indonesia, they have managed more than 32,000 participants for vaccine trials and 2,700 participants for infectious disease clinical trials as malaria, dengue fever, HIV and tuberculosis. In line with the Ministry of Health and BPOM's commitment to developing the clinical trial ecosystem in Indonesia, Equilab has been instrumental in developing over 126 (72 primary health care facilities and 54 hospitals) clinical sites across Indonesia.
